Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines (Q39432416)

11 September 2017

Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines (English)

1 reference

11 September 2017

multiple drug resistance

1 reference

1 reference

B Zheng

1

1 reference

11 September 2017

R Zhou

2

1 reference

11 September 2017

Y Gong

3

1 reference

11 September 2017

X Yang

4

1 reference

11 September 2017

Q Shan

5

1 reference

11 September 2017

7 December 2011

1 reference

International Journal of Laboratory Hematology

11 September 2017

1 reference

11 September 2017

34

1 reference

11 September 2017

3

1 reference

11 September 2017

237-247

1 reference

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia

11 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Targeting the ubiquitin-proteasome pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Drug resistance in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

The ubiquitin-proteasome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-553X.2011.01384.X

10.1111/J.1751-553X.2011.01384.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference